TNYA TENAYA THERAPEUTICS INC

Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference

Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Tenaya management will participate in the Piper Sandler 34th Annual Healthcare Conference, taking place in New York, NY, from November 29th to December 1st.

Details of Tenaya’s participation are as follows:

Panel Discussion: Heart to Heart with CV Players to Discuss 2023 Outlook

Date: November 29, 2022

Time: 2:30 – 3:25 p.m. ET

Fireside Chat

Date: November 30, 2022

Time: 8:30 – 8:55 a.m. ET

A webcast of the Piper Sandler event will be available by visiting the Investors section of . A replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic cardiovascular disorders, as well as for more prevalent heart conditions, through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. For more information, visit .

Contacts

Investors

Michelle Corral

Vice President, Investor Relations and

Corporate Communications

Tenaya Therapeutics

 Media

Wendy Ryan

Ten Bridge Communications





EN
23/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TENAYA THERAPEUTICS INC

 PRESS RELEASE

Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting...

Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy  New Data Confirm TN-301’s Differentiated Mechanism and Opportunities to Positively Address Rare and Prevalent Cardiac, Metabolic and Muscular Conditions Tenaya Plans to Advance TN-301 Toward Phase 2 Clinical Development ORLANDO, Fla. and SOUTH SAN FR...

 PRESS RELEASE

Tenaya Therapeutics Enters into Research Collaboration with Alnylam Ph...

Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics Agreement Combines Tenaya’s Expertise in Identification and Validation ofGenetic Heart Disease Targets with Alnylam’s Ability to Deliver Transformational Therapeutics Tenaya to Receive Up to $10 Million in Upfront Payments in Addition to Research Funding and Milestone Payments of Up to $1.13 Billion SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stag...

 PRESS RELEASE

Tenaya Therapeutics to Participate in the Leerink Partners Global Heal...

Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026 SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Company management will be participating in the upcoming Leerink Partners Global Healthcare Conference taking place from March 9-11, 2026 in Miami, Florida. Faraz Ali, Tenaya’s Chief Executive Officer, wi...

 PRESS RELEASE

Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipate...

Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCM Expects to Report One-Year Cohort 1 Data and Early Cohort 2 Data from RIDGE™-1 Study of TN-401 for PKP2-Associated ARVC in First Half of 2026 Plans to Pursue Alignment on Regulatory Pathways for Lead Gene Therapy Programs in 2026 Raised $60 Million in 4Q25 to Support Runway Through mid-2027 SOUTH SAN FRANCISCO, Calif., J...

 PRESS RELEASE

Tenaya Therapeutics Announces Pricing of Public Offering

Tenaya Therapeutics Announces Pricing of Public Offering SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten public offering of 50,000,000 total units for gross proceeds of $60 million prior to deducting underwriting discounts and commissions and offering expenses.  Tenaya intends to use the net proceeds from the offerin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch